Bartol-Puyal Francisco de Asís, Chacón González María, Arias-Peso Borja, García Navarro Damián, Méndez-Martínez Silvia, Ruiz Del Tiempo María Pilar, Sáez Comet Luis, Pablo Júlvez Luis
Ophthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Miguel Servet Ophthalmology Research Group (GIMSO), Aragón Institute for Health Research (IIS Aragón), 50009 Zaragoza, Spain.
Healthcare (Basel). 2024 Feb 24;12(5):540. doi: 10.3390/healthcare12050540.
To assess vision-related quality of life (VRQoL) in patients with systemic lupus erythematosus (SLE) under treatment with hydroxychloroquine (HCQ), and to find the influencing factors.
Cross-sectional study enrolling SLE patients for less than ten years (Group 1), SLE patients for more than ten years (Group 2), and healthy controls (Group 3). SLE patients should be under treatment with HCQ but without ophthalmological affection. Schirmer test, best-corrected visual acuity (BCVA), axial length (AL) with optical biometry, and swept-source optical coherence tomography-angiography (OCTA) Triton (Topcon) were performed. All participants fulfilled the Impact of Visual Impairment questionnaire, and SLE patients answered the Lupus Impact Tracker (LIT) questionnaire. Additional data were obtained from clinical records.
A totals of 41 eyes (41 patients), 31 eyes (31 patients) and 45 eyes (45 volunteers) were enrolled in the study groups. The mean ages were 41.09 ± 9.56, 45.06 ± 8.47 and 40.25 ± 10.83 years, respectively ( = 0.10). The LIT outcomes were 33.49 ± 20.74 and 35.98 ± 22.66 ( = 0.63), respectively. Group 3 referred to a better VRQoL than Group 2 in all categories and than Group 1 in some of them. A linear regression analysis showed that serum ferritin, SLE activity scales, body-mass index (BMI), age, and BCVA influenced VRQoL. The LIT questionnaire was correlated to two categories of the Impact of Visual Impairment questionnaire (IVI).
Despite no ophthalmological affection, SLE patients refer to poorer VRQoL because of disease activity and a low health-related quality of life, which has a negative influence on VRQoL. This masks the effect of other ophthalmological conditions such as dry eyes. Other variables influencing VRQoL are age and BMI, and BCVA, to a lesser extent.
评估接受羟氯喹（HCQ）治疗的系统性红斑狼疮（SLE）患者的视力相关生活质量（VRQoL），并找出影响因素。
横断面研究纳入病程少于10年的SLE患者（第1组）、病程超过10年的SLE患者（第2组）和健康对照者（第3组）。SLE患者应正在接受HCQ治疗且无眼科病变。进行了泪液分泌试验、最佳矫正视力（BCVA）、光学生物测量法测量眼轴长度（AL）以及扫频源光学相干断层扫描血管造影（OCTA）Triton（拓普康）检查。所有参与者均完成了视力损害影响问卷，SLE患者回答了狼疮影响追踪器（LIT）问卷。从临床记录中获取了其他数据。
研究组分别纳入了41只眼（41例患者）、31只眼（31例患者）和45只眼（45名志愿者）。平均年龄分别为41.09±9.56岁、45.06±8.47岁和40.25±10.83岁（P=0.10）。LIT结果分别为33.49±20.74和35.98±22.66（P=0.63）。在所有类别中，第3组的VRQoL均优于第2组，在某些类别中优于第1组。线性回归分析显示，血清铁蛋白、SLE活动量表、体重指数（BMI）、年龄和BCVA对VRQoL有影响。LIT问卷与视力损害影响问卷（IVI）的两类相关。
尽管没有眼科病变，但由于疾病活动和健康相关生活质量较低，SLE患者的VRQoL较差，这对VRQoL有负面影响。这掩盖了其他眼科疾病如干眼症的影响。影响VRQoL的其他变量是年龄和BMI，以及在较小程度上的BCVA。
